Jul 22, 2025
Each month WaveData collect the prices of brands and generics from pharmacies and dispensing doctors. These come from the price lists and invoices sent to these accounts by their suppliers. This means that what we’re looking at here is the ‘share of voice’ rather than...
Mar 13, 2025
Charles Joynson, WaveData MD, analyses Naproxen E/C Tabs long-term pricing. This consequently triggered pricing and portfolio managers to re-evaluate these products in the light of continuing unprofitability. That then shook some manufacturers out of the market...
Feb 6, 2025
Tadalafil Tabs were launched in November 2017 in competition with Eli Lilly’s Cialis Tabs. Generic prices post launch were around the £10.00 mark, significantly lower than the Cialis reimbursement price at the time which was £54.99. However, eight months after launch...
Feb 6, 2025
Over the last ten years Quetiapine Tabs 100mg 60 has had 4 sets of concessions, making it a risky product to make and distribute. WaveData wanted to find the ‘trigger’ prices which forced manufacturers out of the market due to unprofitability. The first of...
Feb 6, 2025
This suspension is one that has been hovering on the edge of unprofitability for a long time and has seen more concessions granted (32) in 2023 – 2024 that any other generic. Between Nov 2017 and Dec 2019 market prices averaged close to or below £4.00. This...
Nov 15, 2024
With the number of concessions granted by DHSC in October at just 106, the lowest number since May 2022, we wondered if this was a signal of a reduction in the number of shortages or if it was just a blip? To try and understand this issue we needed to get some way of...
